Please use this identifier to cite or link to this item:
Title: Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders
Author: Mallandrich Miret, Mireia
Calpena Campmany, Ana Cristina
Clares Naveros, Beatriz
Parra Coca, Alexander
García López, María Luisa
Soriano, José L.
Francisco Fernández-Campos
Keywords: Oftàlmia
Agents antiinflamatoris
Administració de medicaments
Antiinflammatory agents
Administration of drugs
Issue Date: 15-Feb-2021
Publisher: Future Medicine
Abstract: Aim: The development and optimization of Ketorolac tromethamine-loaded polylactic-co-glycolic acid nanoparticles (KT-NPs) for the treatment of inflammatory processes of the eye. Materials & methods: KT-NPs were developed by factorial design and characterized by assessing their physicochemical properties. Biopharmaceutical behavior studies, ocular tolerance, anti-inflammatory efficacy and bioavailability tests were performed on pigs. Results: Optimized KT-NPs of 112 nm, narrow distribution with encapsulation efficiency near 100% were obtained. KT release followed the Weibull model and there was significantly greater retention in the cornea and sclera than in the commercial reference. KT-NPs showed no signs of ocular irritancy and similar anti-inflammatory efficacy to the commercial reference. Conclusion: KT-NPs were a suitable alternative for the treatment of inflammatory disorders of the anterior and posterior segments of the eye as an alternative to conventional topical formulations.
Note: Versió postprint del document publicat a:
It is part of: Nanomedicine, 2021, vol. 13, num. 3
Related resource:
ISSN: 1743-5889
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
707250.pdf651.8 kBAdobe PDFView/Open    Request a copy

Embargat   Document embargat fins el 15-2-2022

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.